In the editorial from the March issue of VDM, “Pseudoresistance and Pseudoprotection: Is It Time to Abandon Enteric-Coated Aspirin?” editor in chief Frank Criado, MD, FACS, FSVM, discusses results of a recent study of enteric-coated aspirin (Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, Fitzgerald GA. Drug resistance and pseudoresistance: An unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377-385.).
The study evaluated platelet-inhibition response to the administration of a single 325-mg dose of immediate-release or enteric-coated aspirin in 400 healthy adults from 18 years old to 55 years old to assess the activity of cyclooxygenase-1. Results showed that all those receiving immediate-release aspirin were responders, but up to 49% of those given enteric-coated aspirin were nonresponders. Not only that, but also nonresponders turned into responders when given immediate-release aspirin.
“The study’s outcome is nothing short of an eye-opener that could have major impact on millions taking aspirin every day when and if enteric coating can be confirmed to be the culprit that causes pseudoresistance to the drug through absorption interference, and without providing proven protection against gastric side effects,” writes Dr. Criado.
Read Dr. Criado’s editorial in the March 2013 issue of Vascular Disease Management.